Show simple item record

dc.contributor.advisorShahidi, Nikzad
dc.contributor.advisorNoei, Shabnam
dc.contributor.authorAdami, Zahra
dc.date.accessioned2024-05-18T06:57:10Z
dc.date.available2024-05-18T06:57:10Z
dc.date.issued2023en_US
dc.identifier.urihttps://dspace.tbzmed.ac.ir:443/xmlui/handle/123456789/70725
dc.description.abstractMeniere's disease is a chronic condition characterized by severe episodes of vertigo, hearing loss, tinnitus, and auditory pressure. Cinnarizine is a medication that can be used for controlling these symptoms. By reducing vascular contractions and blood viscosity, this medication can effectively manage these symptoms. Currently, medicinal chewing gum (MCG) is a drug delivery system that has made significant advancements in researches and is expected to be produced with superior standards in the future. This drug delivery system can provide drugs or nutrients in the form of a formulation with an extended and continuous release. Objective:The objective of this study is to design and formulate medicinal chewing gum containing cinnarizine for the treatment of Meniere's disease. Additionally, the clinical effects of the obtained formulations will be examined.Materials and Methods:First, a calibration curve for the medication was drawn, and then medicated chewing gums were prepared using suitable base materials. The physicochemical properties of the prepared gums, including hardness, erosion, and physical stability, were examined. The drug release profile from the gum base in a simulated oral environment was evaluated using a specifically designed device that could mimic chewing action. Finally, the clinical clinical effects of formulated chewing gums will be examined on human patients. Conclusion:Upon examination of the erosion, release, content uniformity tests, and clinical evaluatory results, it was found that the formulated chewing gums exhibit comparable clinical efficacy to cinnarizine tablets. Based on the acquired data and favorable advantages of formulated chewing gums in comparison to tablets, this formulation possesses significant potential as an alternative to these pharmaceutical formulations.en_US
dc.language.isofaen_US
dc.publisherTabriz University of Medical Sciences, School of Pharmacyen_US
dc.relation.isversionofhttps://dspace.tbzmed.ac.ir:443/xmlui/handle/123456789/70722en_US
dc.subjectmedicinal chewing gumen_US
dc.subjectcinnarizineen_US
dc.subjectMeniere's diseaseen_US
dc.subjectmotion sicknessen_US
dc.titleDesign and formulation of cinnarizine chewing gum for treatment of motion sickness or Ménière's diseaseen_US
dc.typeThesisen_US
dc.contributor.supervisorJavadzadeh, Yousef
dc.contributor.supervisorGhafari, Saba
dc.identifier.callno4456en_US
dc.description.disciplinePharmacyen_US
dc.description.degreePharm Den_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record